TABLE 3.
Switchers and discontinuers: all DOAC, by individual DOAC (at 3, 6, 12 months).
| Netherlands (Mondriaan) | Denmark (DNR) | Germany (AOK NORDWEST) | Germany (Bavarian claims) a | Spain (BIFAP) | Spain (SIDIAP) | United Kingdom (CPRD) | France (EGB) | |
|---|---|---|---|---|---|---|---|---|
| All DOACs | 460 | 44,876 | 21,718 | 84,276 | 14,161 | 11,962 | 6,931 | 2021 |
| Number of switchers related to any DOACs Nº (%) | 11 (2.4%) | 5,665 (12.6%) | 3,491 (16.1%) | 11,791 (14.0%) | 1,249 (8.8%) | 753 (6.3%) | 457 (6.6%) | 312 (15.4%) |
| Switchers at 1–3 months Nº (%) | 10 (2.2%) | 2,914 (6.5%) | 1,217 (5.6%) | 6,176 (7.3%) | 859 (6.1%) | 393 (3.3%) | 294 (4.2%) | 172 (8.5%) |
| Switchers at 1–6 months Nº (%) | 10 (2.2%) | 3,906 (8.7%) | 1827 (8.4%) | 7,551 (8.9%) | 1,000 (7.1%) | 485 (4.0%) | 363 (5.2%) | 219 (10.8%) |
| Switchers at 1–12 months Nº (%) | 11 (2.4%) | 4,734 (10.5%) | 2,455 (11.3%) | 9,409 (11.2%) | 1,121 (7.9%) | 606 (5.1%) | 417 (6.0%) | 263 (13.1%) |
| Number of discontinuers related to any DOACs Nº (%) | 241 (52.4%) | 17,795 (39.6%) | 11,170 (51.4%) | 66,905 (79.4%) | 4,540 (32.1%) | 5,451 (45.6%) | 1,228 (17.7%) | 621 (30.7%) |
| Discontinuers at 1–3 months Nº (%) | 165 (35.9%) | 3,678 (8.2%) | 3,158 (14.5%) | 32,859 (39.0%) | 1809 (12.8%) | 2,433 (20.3%) | 638 (9.2%) | 290 (14.3%) |
| Discontinuers at 1–6 months Nº (%) | 203 (44.1%) | 7,731 (12.2%) | 5,961 (27.4%) | 41,785 (49.6%) | 2,680 (18.9%) | 3,281 (27.4%) | 888 (12.8%) | 414 (20.5%) |
| Discontinuers at 1–12 months Nº (%) | 235 (51.1%) | 12,316 (27.4%) | 8,435 (38.8%) | 53,857 (63.9%) | 3,612 (25.5%) | 4,234 (35.4%) | 1,109 (16.0%) | 538 (26.6%) |
| Dabigatran | 99 | 23,308 | 3,968 | 14,729 | 3,863 | 4,784 | 1,265 | 479 |
| Number of switchers related to dabigatran Nº (%) | 5 (5.1%) | 3,942 (16.9%) | 1,126 (28.4%) | 3,923 (26.6%) | 488 (12.6%) | 457 (9.5%) | 183 (14.5%) | 120 (25.0%) |
| Switchers at 1–3 months Nº (%) | 4 (4.0%) | 1854 (7.9%) | 351 (8.8%) | 1886 (12.8%) | 310 (8.0%) | 218 (4.5%) | 105 (8.3%) | 54 (11.3%) |
| Switchers at 1–6 months Nº (%) | 4 (4.0%) | 2,452 (10.9%) | 531 (13.4%) | 2,347 (15.9%) | 371 (9.6%) | 272 (5.7%) | 139 (11.0%) | 72 (15.0%) |
| Switchers at 1–12 months Nº (%) | 5 (5.0%) | 3,158 (13.5%) | 708 (17.8%) | 2,934 (19.9%) | 422 (10.9%) | 352 (7.3%) | 161 (12.7%) | 96 (20.0%) |
| Number of discontinuers related to Dabigatran Nº (%) | 67 (67.7%) | 11,688 (50.1%) | 2,387 (60,2%) | 10,497 (71.3%) | 1,615 (41.8%) | 2,798 (58,5%) | 353 (27.9%) | 184 (38.4%) |
| Mean treatment duration days (SD) | 179.2 (224.2) | 397.1 (415.2) | 443.1 (438.4) | 348.2 (328.5) | 360.4 (337.5) | |||
| Discontinuers at 1–3 months Nº (%) | 40 (40.4%) | 2,335 (10.1%) | 485 (12.2%) | 3,850 (26.1%) | 603 (16.0%) | 1,174 (24.5%) | 146 (11.5%) | 73 (15.2%) |
| Discontinuers at 1–6 months Nº (%) | 50 (50.5%) | 4,794 (20.6%) | 921 (23.2%) | 4,739 (32.2%) | 885 (23.0%) | 1,574 (32.9%) | 225 (17.8%) | 111 (23.2%) |
| Discontinuers at 1–12 months Nº (%) | 64 (64.6%) | 7,559 (32.4%) | 1,368 (34.5%) | 6,172 (41.9%) | 1,225 (31.7%) | 2053 (42.9%) | 294 (23.2%) | 151 (31.5%) |
| Apixaban | 72 | 10,358 | 5,460 | 17,339 | 3,693 | 2,728 | 2060 | 396 |
| Number of switchers related to apixaban Nº (%) | 2 (2.8%) | 540 (5.2%) | 366 (6.7%) | 1,014 (5.8%) | 197 (5.3%) | 75 (2.7%) | 58 (2.8%) | 27 (6.8%) |
| Switchers at 1–3 months Nº (%) | 2 (2.8%) | 346 (3.3%) | 201 (3.7%) | 706 (4.1%) | 148 (4.0%) | 47 (1.7%) | 41 (2.0%) | 22 (5.6%) |
| Switchers at 1–6 months Nº (%) | 2 (2.8%) | 436 (4.2%) | 266 (4.9%) | 835 (4.8%) | 170 (4.6%) | 57 (2.1%) | 48 (2.3%) | 27 (6.8%) |
| Switchers at 1–12 months Nº (%) | 2 (2.8%) | 514 (5.0%) | 337 (6.2%) | 970 (5.9%) | 191 (5.2%) | 67 (2.4%) | 54 (2.6%) | 27 (6.8%) |
| Number of discontinuers related to Apixaban Nº (%) | 31 (12.9%) | 2,475 (23.9%) | 2,468 (45.2%) | 13,691 (79.0%) | 846 (23.0%) | 848 (31.1%) | 269 (13.1%) | 76 (19.2%) |
| Mean treatment duration days (SD) | 118.9 (139.6) | 236.8 (203.2) | 266.3 (214.7) | 217.2 (193.9) | 199.8 (157.1) | |||
| Discontinuers at 1–3 months Nº (%) | 19 (26.4%) | 576 (5.6%) | 781 (14.3%) | 7,410 (42.7%) | 357 (10.0%) | 409 (15.0%) | 152 (7.4%) | 44 (11.1%) |
| Discontinuers at 1–6 months Nº (%) | 27 (37.5%) | 1,319 (12.7%) | 1,525 (27.9%) | 9,587 (55.3%) | 571 (15.5%) | 566 (20,7%) | 210 (10.2%) | 59 (14.9%) |
| Discontinuers at 1–12 months Nº (%) | 31 (43.1%) | 2079 (20.1%) | 2,132 (39.0%) | 12,060 (69.5%) | 770 (20.8%) | 728 (26.7%) | 254 (12.3%) | 75 (18.9%) |
| Netherlands (Mondriaan) | Denmark (NRD) | Germany (AOK NORDWEST) | Germany (Bavarian claims) a | Spain (BIFAP) | Spain (SIDIAP) | United Kingdom (CPRD) | France (EGB) | |
| Rivaroxaban | 289 | 11,210 | 12,290 | 52,208 | 6,605 | 4,450 | 3,606 | 1,146 |
| Number of switchers related to rivaroxaban Nº (%) | 4 (1.4%) | 1,183 (10.5%) | 1999 (16.3%) | 6,854 (13.1%) | 564 (8.5%) | 221 (5.0%) | 216 (6.0%) | 165 (14.4%) |
| Switchers at 1–3 months Nº (%) | 3 (1.1%) | 714 (6.4%) | 665 (5.4%) | 3,612 (6.9%) | 401 (6.1%) | 128 (2.9%) | 148 (4.1%) | 96 (8.3%) |
| Switchers at 1–6 months Nº (%) | 3 (1.1%) | 928 (8.3%) | 1,030 (8.4%) | 4,369 (8.3%) | 459 (7.0%) | 156 (3.5%) | 176 (4.9%) | 120 (10.5%) |
| Switchers at 1–12 months Nº (%) | 4 (1.4%) | 1,062 (9.5%) | 1,410 (11.5%) | 5,505 (10.5%) | 508 (7.7%) | 187 (4.2%) | 202 (5.6%) | 140 (12.2%) |
| Number of discontinuers related to any rivaroxaban Nº (%) | 143 (51.3%) | 3,632 (32.4%) | 6,315 (51,4%) | 42,717 (81.8%) | 2079 (31.5%) | 1805 (40.5%) | 606 (16.8%) | 361 (31.5%) |
| Mean treatment duration days (SD) | 177.7 (199.2) | 342.1 (322.4) | 339.2 (313.9) | 246.7 (235.8) | 362.5 (333.2) | |||
| Discontinuers at 1–3 months Nº (%) | 106 (38.0%) | 767 (6.8%) | 1892 (15.4%) | 21,599 (41.4%) | 849 (13.0%) | 850 (19.1%) | 340 (9.4%) | 173 (15.1%) |
| Discontinuers at 1–6 months Nº (%) | 126 (45.2%) | 1,618 (14.4%) | 3,515 (28.6%) | 27,459 (52.6%) | 1,224 (19.0%) | 1,141 (25.6%) | 453 (12.6%) | 244 (21.3%) |
| Discontinuers at 1–12 months No (%) | 140 (50.2%) | 2,678 (23.9%) | 4,935 (40.2%) | 35,625 (68.2%) | 1,617 (24.0%) | 1,453 (32.6%) | 561 (15.5%) | 312 (27.2%) |
a
In the Bavarian databases due to the quarterly definition, an interruption of one quarter could not necessarily mean a termination of the therapy in all cases.